Drug
WGI-0301
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
0(0%)
Phase Distribution
Ph phase_2
1
33%
Ph phase_1
2
67%
Phase Distribution
2
Early Stage
1
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
2(66.7%)
Phase 2Efficacy & side effects
1(33.3%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Active(2)
Other(1)
Detailed Status
Not yet recruiting2
unknown1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
N/A
Most Advanced
Phase 2
Trials by Phase
Phase 12 (66.7%)
Phase 21 (33.3%)
Trials by Status
not_yet_recruiting267%
unknown133%
Recent Activity
0 active trials
Showing 3 of 3
not_yet_recruitingphase_1
Phase 2 Study of WGI-0301 Plus Lenvatinib in Patients With Advanced HCC
NCT07540832
not_yet_recruitingphase_2
Phase 2 Study of WGI-0301 Plus Nivolumab in Patients With HCC and RCC
NCT07494435
unknownphase_1
A Phase I First in Human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of WGI-0301 in Patients With Advanced Solid Tumors
NCT05267899
Clinical Trials (3)
Showing 3 of 3 trials
NCT07540832Phase 1
Phase 2 Study of WGI-0301 Plus Lenvatinib in Patients With Advanced HCC
NCT07494435Phase 2
Phase 2 Study of WGI-0301 Plus Nivolumab in Patients With HCC and RCC
NCT05267899Phase 1
A Phase I First in Human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of WGI-0301 in Patients With Advanced Solid Tumors
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3